Display options
Share it on

Adv Pharmacol Sci. 2011;2011:204501. doi: 10.1155/2011/204501. Epub 2011 Jun 16.

Pharmacokinetics of p-Aminohippuric Acid and Inulin in Rabbits with Aristolochic Acid Nephropathy.

Advances in pharmacological sciences

Chiao-Shih Tseng, Shih-Ming Chen, Shu-Chen Chien, Kuang-Yang Hsu

Affiliations

  1. College of Pharmacy, Taipei Medical University, 250 Wu-Hsing Street, Taipei 11014, Taiwan.

PMID: 21738526 PMCID: PMC3124128 DOI: 10.1155/2011/204501

Abstract

The characteristics of aristolochic acid nephropathy (AAN) are interstitial fibrosis and atrophy of the proximal tubules, but with no change in glomeruli. To investigate the effects of AA on renal functions and the pharmacokinetics (PKs) of p-aminohippuric acid (PAH) and inulin, New Zealand white rabbits were used in this study. The plasma concentrations of PAH and inulin were determined by validated HPLC methods. After a single intravenous administration of 0.5 mg/kg aristolochic acid sodium (AANa), rabbits exhibited mild to moderate nephrotoxicity on the 7th day. Significant tubulointerstitial damage to kidney specimens was found, but there were no remarkable glomerular changes. Clearance rates of PAH and inulin both significantly decreased in AANa-treated rabbits. In addition, there was a significant correlation among the degree of tubulointerstitial changes and PK parameters of PAH after AANa administration, but no correlation was noted with the PKs of inulin. With mild to moderate AAN in rabbits, the renal plasma flow significantly decreased by 55%, and the glomerular filtration rate also significantly decreased by 85%. In conclusion, major renal lesions were found on proximal tubules after AANa administration. The PKs of PAH and inulin significantly changed, and kidney functions, including the RPF and GFR, were reduced.

References

  1. Kidney Int. 1988 Jun;33(6):1078-83 - PubMed
  2. Hum Pathol. 2000 Dec;31(12):1491-7 - PubMed
  3. N Engl J Med. 2003 Oct 16;349(16):1576-7 - PubMed
  4. Clin Nephrol. 1998 Mar;49(3):167-72 - PubMed
  5. J Am Soc Nephrol. 2002 Feb;13(2):431-436 - PubMed
  6. Kidney Int. 1992 Jan;41(1):80-7 - PubMed
  7. Lancet. 1993 Feb 13;341(8842):387-91 - PubMed
  8. Xenobiotica. 1987 Aug;17(8):981-91 - PubMed
  9. Lancet. 1999 Aug 7;354(9177):481-2 - PubMed
  10. Pflugers Arch. 2000 Jul;440(3):337-50 - PubMed
  11. Clin Pharmacokinet. 2003;42(14):1193-211 - PubMed
  12. Drug Saf. 2003;26(1):33-48 - PubMed
  13. Toxicon. 2007 Aug;50(2):180-8 - PubMed
  14. Pharmacol Ther. 2006 Mar;109(3):399-412 - PubMed
  15. Drug Metab Dispos. 1999 Jan;27(1):81-5 - PubMed
  16. Clin Pharmacokinet. 1998 May;34(5):375-404 - PubMed
  17. Kidney Int. 2001 Jun;59(6):2164-73 - PubMed
  18. Life Sci. 1995;56(4):231-9 - PubMed
  19. Nephrologie. 1998;19(1):15-20 - PubMed
  20. Am J Kidney Dis. 1994 Aug;24(2):172-80 - PubMed
  21. Kidney Int. 1994 Jun;45(6):1680-8 - PubMed
  22. Lancet. 1994 Jan 15;343(8890):174 - PubMed
  23. Nephrol Dial Transplant. 1996 Jul;11(7):1359-60 - PubMed
  24. Arch Toxicol. 2006 Aug;80(8):524-32 - PubMed
  25. Life Sci. 2002 Jul 5;71(7):779-87 - PubMed
  26. Am J Physiol Renal Physiol. 2001 Aug;281(2):F197-205 - PubMed
  27. Pediatr Nephrol. 2000 May;14(5):370-5 - PubMed
  28. Drug Metab Rev. 1986;17(3-4):331-48 - PubMed
  29. Nephrol Dial Transplant. 2007 Feb;22(2):445-56 - PubMed
  30. Am J Physiol. 1949 Jun;157(3):387-93 - PubMed
  31. Pediatr Nephrol. 2006 Apr;21(4):577-9 - PubMed
  32. J Pharm Pharmacol. 2004 Feb;56(2):221-9 - PubMed
  33. N Engl J Med. 2000 Jun 8;342(23):1686-92 - PubMed
  34. Best Pract Res Clin Anaesthesiol. 2004 Mar;18(1):21-36 - PubMed
  35. Nephrol Dial Transplant. 2002 Mar;17(3):524-5 - PubMed
  36. Am J Nephrol. 2006;26(4):363-71 - PubMed
  37. J Altern Complement Med. 1998 Spring;4(1):9-13 - PubMed
  38. Life Sci. 1997;61(22):2157-65 - PubMed
  39. Am J Nephrol. 2001 Nov-Dec;21(6):441-8 - PubMed
  40. Proc (Bayl Univ Med Cent). 2000 Oct;13(4):334-7 - PubMed

Publication Types